Evidence map›Paper›PMID 38684571›Full record

ReviewStem cell reviews and reports2024

The Evolutionary Route of in vitro Human Spermatogenesis: What is the Next Destination?

Merve Gizer, Selin Önen, Petek Korkusuz

Abstract readReview
In one paragraph

Review in Stem cell reviews and reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Decellularized testicular bio-scaffolds driveFrontiers in bioengineering and biotechnology · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. NAM journal · 2025
    Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Merve GizerDepartment of Stem Cell Sciences, Graduate School of Health Sciences, Hacettepe University, 06100, Ankara, Turkey.
Selin ÖnenMETU MEMS Center, 06530, Ankara, Turkey.
Petek KorkusuzMETU MEMS Center, 06530, Ankara, Turkey. petek@hacettepe.edu.tr.ORCID 0000-0002-7553-3915

Funding

Hacettepe Üniversitesi TSA-2021-19204Türkiye Bilimsel ve Teknolojik Araştırma Kurumu 120S254
6 · The paper itself

Abstract

Malfunction in spermatogenesis due to genetic diseases, trauma, congenital disorders or gonadotoxic treatments results in infertility in approximately 7% of males. The behavior of spermatogonial stem cells (SSCs) within three-dimensional, multifactorial, and dynamic microenvironment implicates a niche that serves as a repository for fertility, since can serve as a source of mature and functional male germ cells. Current protocols enable reprogramming of mature somatic cells into induced pluripotent stem cells (iPSCs) and their limited differentiation to SSCs within the range of 0-5%. However, the resulting human iPSC-derived haploid spermatogenic germ cell yield in terms of number and functionality is currently insufficient for transfer to infertility clinic as a therapeutic tool. In this article, we reviewed the evolution of experimental culture platforms and introduced a novel iPSCs-based approach for in vitro spermatogenesis based on a niche perspective bearing cellular, chemical, and physical factors that provide the complex arrangement of testicular seminiferous tubules embedded within a vascularized stroma. We believe that bioengineered organoids supported by smart bio-printed tubules and microfluidic organ-on-a-chip systems offer efficient, precise, personalized platforms for autologous pluripotent stem cell sources to undergo the spermatogenetic cycle, presenting a promising tool for infertile male patients with complete testicular aplasia.

Indexed as

Induced Pluripotent Stem CellsSpermatogenesisCell DifferentiationHumansMaleStem Cell NicheInduced Pluripotent Stem CellsIn vitro SpermatogenesisMale Factor InfertilitySpermatogonial Stem Cells

Identifiers

PMID38684571
PMCPMC11319530

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.